Prediction of thrombotic and bleeding events after percutaneous coronary intervention: CREDO-Kyoto thrombotic and bleeding risk scores

Pharmacology, Toxicology and Pharmaceutical Science

• Thrombosis 100%
• Everolimus 66%
• Peripheral Vascular Disease 66%
• Brain Ischemia 33%
• Chronic Total Occlusion 33%
• Sirolimus 33%
• Umirolimus 33%
• Tissue Plasminogen Activator 33%
• Thrombocytopenia 33%
• Stent Thrombosis 33%
• Streptokinase 33%

Medicine and Dentistry

• Everolimus 66%
• Peripheral Vascular Disease 66%
• Thrombocytopenia 33%
• Antithrombotic Therapy 33%
• Streptokinase 33%
• Chronic Total Occlusion 33%
• Umirolimus 33%
• Rapamycin 33%
• Stent Thrombosis 33%
• Tissue Plasminogen Activator 33%